News | July 26, 2025
Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Subscribe To Our Newsletter & Stay Updated
